RVNC - Revance Therapeutics EPS beats by $0.11 beats on revenue May, 10 2021 04:10 PM Revance Therapeutics Inc. Revance Therapeutics (RVNC): Q1 GAAP EPS of -$1.08 beats by $0.11.Revenue of $13.2M (+21900.0% Y/Y) beats by $2.37M.Press Release For further details see: Revance Therapeutics EPS beats by $0.11, beats on revenue